Investigation of multidrug resistance in cultured human renal cell carcinoma cells by 31P-NMR spectroscopy and treatment survival assays

Magnetic Resonance Materials in Physics, Biology and Medicine

Volumn 18, Issue 3, 2005, Pages 144-161

  Hull, W E ^a   Lutz, N W ^a,d   Franks, S E ^a   Frank, M H ^b,c   Pomer, S ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

31P NMR spectroscopy; Metabolomics; Multidrug resistance; P glycoprotein; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; CALCIUM ANTAGONIST; CREATINE PHOSPHATE; DILTIAZEM; GLYCEROPHOSPHOETHANOLAMINE; GLYCEROPHOSPHORYLCHOLINE; PHOSPHATE; PHOSPHORYLCHOLINE; RECOMBINANT ALPHA2B INTERFERON; VINBLASTINE; VINBLASTINE SULFATE;

ARTICLE; CANCER CELL CULTURE; CELL CULTURE; CELL LINE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; HUMAN; HUMAN TISSUE; INCUBATION TIME; KIDNEY CANCER; METABOLITE; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DILTIAZEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHATES; PHOSPHORUS ISOTOPES; TREATMENT OUTCOME; VINBLASTINE;

EID: 23844480008     PISSN: 09685243     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10334-005-0107-7     Document Type: Article

References (80)

1. Griniatsos J, Michail PO, Menenakos C, Hatzianastasiou D, Koufos C, Bastounis E (2003) Metastatic renal clear cell carcinoma mimicking stage IV lung cancer. Intl Urol Nephrol 35:15-17
2. Bichler K-H, Wechsel HW (1999) The problematic nature of metastasized renal cell carcinoma. Anticancer Res 19:1463-1466
3. Bak M, Efferth T, Mickisch G, Mattern J, Volm M (1990) Detection of drug resistance and P-glycoprotein in human renal cell carcinomas. Eur Urol 17:72-75
4. Kakehi Y, Kanamaru H, Yoshida O, Ohkubo H, Nakanishi S, Gottesman MM, Pastan I (1988) Measurement of multidrug-resistance messenger RNA in urogenital cancers; elevated expression in renal cell carcinoma is associated with intrinsic drug resistance. J Urol 139:862-865
5. Chabner BA, Fojo A (1989) Multidrug resistance: P-glycoprotein and its allies-the elusive foes. J Natl Cancer Inst 81:910-913
6. Mickisch GH (1993) Current status and future directions of research on multidrug resistance. The impact of contemporary biotechnology. Urol Res 21:79-81
7. Rothenberg M, Ling V (1989) Multidrug resistance: molecular biology and clinical relevance. J Natl Cancer Inst 81:907-910
8. Naito M, Tsuruo T (1989) Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement. Cancer Res 49:1452-1455
9. Dalton WS, Sikic BI (1994) The multidrug resistance gene (MDR1) represents a potential target for reversing drug resistance in human malignancies. J NIH Res 6:54-58
10. Pastan I, Gottesman MM (1991) Multidrug resistance. Annu Rev Med 42:277-286
11. Horio M, Gottesman MM, Pastan I (1988) ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci USA 85:3580-3584
12. Mickisch GH, Roehrich K, Koessig J, Forster S, Tschada RK, Alken PM (1990) Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma. J Urol 144:755-759
13. Naito S, Koike K, Ono M, Machida T, Tasaka S, Kiue A, Koga H, Kumazawa J (1998) Development of novel reversal agents, imidazothiazole derivatives, targeting MDR1-and MRP-mediated multidrug resistance. Oncology Res 10:123-132
14. Silverman JA (1999) Multidrug-resistance transporters: In: Amidon GL, Sadee W (eds) Membrane transporters as drug targets, vol 12. Kluwer Academic/Plenum Publishers, New York, pp 353-386
15. Ernest S, Bello-Reuss E (1998) P-glycoprotein functions and substrates: Possible roles of MDR1 gene in the kidney. Kidney Int 53:S11-S17
16. Higgins CF, Gottesman MM (1992) Is the multidrug transporter a flippase? Trends Biochem Sci 17:18-21
17. Van Helvoort A, Smith AJ, Sprang H, Fritzsche I, Schinkel AH, Borst P, Van Meer G (1996) MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87:507-517
18. Fojo T, Bates S (2003) Strategies for reversing drug resistance. Oncogene 22:7512-7523
19. Negendank WG (1992) Studies of human tumors by MRS: A review. NMR Biomed 5:303-324
20. Kaplan O, Jaroszewski JW, Clarke R, Fairchild CR, Schoenlein P, Goldenberg S, Gottesman MM, Cohen JS (1991) The multidrug resistance phenotype: 31P nuclear magnetic resonance characterization and 2-deoxyglucose toxicity. Cancer Res 51:1638-1644
21. Le Moyec L, Tatoud R, Degeorges A, Calabresse C, Bauza G, Eugène M, Calvo F (1996) Proton nuclear magnetic resonance spectroscopy reveals cellular lipids involved in resistance to adriamycine and taxol by the K562 leukemia cell line. Cancer Res 56:3461-3467
22. Le Moyec L, Legrand O, Larue V, Kawakami M, Marie J-P, Calvo F, Hantz E, Taillandier E (2000) Magnetic resonance spectroscopy of cellular lipid extracts from sensitive, resistent and reverting K562 cells and flow cytometry for investigating the P-glycoprotein function in resistance reversion. NMR Biomed 13:92-101
23. Mannechez A, Collet B, Payen L, Lecureur V, Fardel O, Le Moyec L, De Certaines J-D, Leray G (2001) Differentiation of the P-gp and MRP1 multidrug resistance systems by mobile lipid 1H-NMR spectroscopy and phosphatidylserine externalization. Anticancer Res 21:3915-3920
24. Santini MT, Romano R, Rainaldi G, Filippini P, Bravo E, Porcu L, Motta A, Calcabrini A, Meschini S, Indovina PL, Arancia (2001) The relationship between 1H-NMR mobile lipid intensity and cholesterol in two human tumor multidrug resistant cell lines (MCF-7 and LoVo). Biochim Biophys Acta 1531:111-131
25. Venkatesan PV, Saravanan K, Nagarajan B (1998) Characterization of multidrug resistance and monitoring of tumor response by combined 31P and 1H nuclear magnetic resonance spectroscopic analysis. Anti-Cancer Drugs 9:449-456
26. Vivi A, Tassini M, Ben-Horin H, Navon G, Kaplan O (1997) Comparison of action of the anti-neoplastic drug Ionidamine on drug-sensitive and drug-resistant human breast cancer cells: 31P and 13C nuclear magnetic resonance studies. Breast Cancer Res Treat 43:15-25
27. DeVita VT, Hellman S, Rosenberg SA (1997) Cancer, principles and practice of oncology, vol 1 Lippincott-Raven, Philadelphia New York
28. Efferth T, Dunn TA, Berlion M, Langenbahn H, Pommerenke EW, Volm M (1993) Reversal of inherent multidrug-resistance in primary human renal cell carcinoma cell cultures by S 9788. Anticancer Res 13:905-908
29. Efferth T, Lohrke H, Volm M (1990) Correlations between natural resistance to doxorubicin, proliferative activity, and expression of P-glycoprotein 170 in human kidney tumor cell lines. Urol Res 18:309-312
30. Efferth T, Lohrke H, Volm M (1989) Reciprocal correlation between expression of P-glycoprotein and accumulation of rhodamine 123 in human tumors. Anticancer Res 9:1633-1637
31. Mosman T (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
32. Frank MH, Pomer S (1999) Interferon alpha2b differentially affects proliferation of two human renal cell carcinoma cell lines differing in the P-glycoprotein-associated multidrug-resistant phenotype. J Cancer Res Clin Oncol 125:117-120
33. Franks SE, Kuesel AC, Lutz NW, Hull WE (1996) 31P MRS of human tumor cells: Effects of culture media and conditions on phospholipid metabolite concentrations. Anticancer Res 16:1365-1374
34. Kuesel AC, Donnelly SM, Halliday W, Halliday GR, Sutherland GR, Smith ICP (1994) Mobile lipids and heterogeneity of brain tumours as detectable by ex vivo 1H MR specroscopy. NMR Biomed 7:172-180
35. Shedd SF, Lutz NW, Hull WE (1993) The influence of medium formulation on phosphomonoester and UDP-hexose levels in cultured human colon tumor cells as observed by 31P NMR spectroscopy. NMR Biomed 6:254-263
36. Lutz NW, Kuesel AC, Hull WE (1993) A 1H NMR method for determining temperature in cell culture perfusion systems. Magn Reson Med 29:113-118
37. Kuesel AC, Graschew G, Hull WE, Lorenz W, Thielmann HW (1990) 31P NMR studies of cultured human tumor cells Influence of pH on phospholipid metabolite levels and the detection of cytidine 5′-diphosphate choline. NMR Biomed 3:78-89
38. Rofstad EK, DeMuth P, Fenton BM, Sutherland RM (1988) 31P nuclear magnetic resonance spectroscopy studies of tumor energy metabolism and its relationship to intracapillary oxyhemoglobin saturation status and tumor hypoxia. Cancer Res 48:5440-5446
39. Stryer L (1995) Biochemistry, 4th edn. WH Freeman and Company, New York
40. StatView (1999) Reference book. SAS Institute, Cary
41. Huland E, Heinzer H, Timm S, Aalamian M, Huland H (2002) Immuntherapie des metastasierenden Nierenzellkarzinoms in Deutschland. Urologe (A) 41:282-287
42. Krug J, Fritzsch J, Aust G (1995) Induction of insulin antibodies and insulin allergy under alpha-interferon treatment of renal cell carcinoma in a patient with insulin-treated diabetes mellitus - a case report. Int Arch Allergy Immunol 106:169-172
43. Podo F (1999) Tumour phospholipid metabolism. NMR Biomed 12:413-439
44. Mulquiney PJ, Kuchel PW (1999) Using the beta/alpha peak-height ratio of ATP in 31P spectra to measure free [Mg2+]: theoretical and practical problems. NMR Biomed 12:217-220
45. Willcocks JP, Mulquiney PJ, Ellory JC, Veech RL, Radda GK, Clarke K (2002) Simultaneous determination of low free Mg2+ and pH in human sickle cells using 31P NMR spectroscopy. J Biol Chem 277:49911-49920
46. Fogler WE, Pearson JW, Volker K, Ariyoshi K, Watabe H, Riggs CW, Wiltrout RH, Longo DL (1995) Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody. J Natl Cancer Inst 87:94-104
47. Kang Y, Perry RR (1994) Effect of alpha-interferon on P-glycoprotein expression and function and on verapamil modulation of doxorubicin resistance. Cancer Res 54:2952-2958
48. Lucero Gritti MF, Beviacqua M, Bordenave RH, Rumi LS (2001) Interferon-alpha 2b modulation of doxorubicin sensitivity in a multidrug resistant cell line. J Exp Clin Res 20:393-400
49. Hofmockel G, Bassukas ID, Wittmann A, Dammrich J (1997) Is the expression of multidrug resistance gene product a prognostic indicator for the clinical outcome of patients with renal cancer? Br J Urol 80:11-17
50. Oudard S, Levalois C, Andrieu JM, Bougaran J, Validire P, Thiounn N, Poupon MF, Fourme E, Chevillard S (2002) Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome. Anticancer Res 22:121-128
51. Giaccone G, Pinedo HM (1996) Reversal of MDR in solid tumors: In: Gupta S, Tsuruo T (eds) Multidrug resistance in cancer cells. Wiley, Chichester, pp 473-491
52. Abraham EH, Prat AG, Gerweck L, Seneveratne T, Arceci RJ, Kramer R, Guidotti G, Cantiello HF (1993) The multidrug resistance (mdrl) gene product functions as an ATP channel. Proc Natl Acad Sci USA 90:312-316
53. Hartmann JT, Bokemeyer C (1999) Chemotherapy for renal cell carcinoma. Anticancer Res 19:1541-1544
54. Efferth T, Thelen P, Schulten HG, Bode ME, Granzen B, Beniers AJ, Mertens R, Ringert RH, Gefeller O, Jakse G, Fuzesi L (2001) Differential expression of the multidrug resistance-related protein MRP1 in the histological compartments of nephroblastomas. Int J Oncol 19:367-371
55. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2:48-58
56. Kellen JA (1995) Alternative mechanisms of multidrug resistance in cancer. Birkhaeuser, Boston
57. Scheltema JMW, Romijn JC, Van Steenbrugge GJ, Beck WT, Schroeder FH, Mickisch GH (1997) Decreased levels of topoisomerase IIa in human renal cell carcinoma lines resistant to etoposide. J Cancer Res Clin Oncol 123:546-554
58. Scheltema JMW, Romijn JC, Van Steenbruggev, Schroeder FH, Mickisch GH (2001) Inhibition of apoptotic proteins causes multidrug resistance in renal carcinoma cells. Anticancer Res 21:3161-3166
59. Sikic B, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G (1997) Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 40:S13-S19
60. Cohen JS, Lyon RC, Chen C, Faustino PJ, Batist G, Shoemaker M, Rubalcaba E, Cowan KH (1986) Differences in phosphate metabolite levels in drug-sensitive and -resistant human breast cancer cell lines determined by 31P magnetic resonance spectroscopy. Cancer Res 46:4087-4090
61. Lavie Y, Fiucci G, Czarny M, Liscovitch M (1999) Changes in membrane microdomains and caveolae constituents in multidrug-resistant cancer cells. Lipids 34:S57-S63
62. Sharom FJ (1997) The P-glycoprotein multidrug transporter: interactions with membrane lipids, and their modulation of activity. Biochem Soc Trans 25:1088-1096
63. Ruiz-Cabello J, Cohen JS (1992) Phospholipid metabolites as indicators of cancer cell function. NMR Biomed. 5:226-33
64. Evelhoch JL, Keller NA, Corbett TH (1987) Response-specific adriamycin sensitivity markers provided by in vivo 31P nuclear magnetic resonance spectroscopy in murine mammary adenocarcinomas. Cancer Res 47:3396-3401
65. Tausch-Treml R, Kopf-Maier P, Baumgart F, Gewiese B, Ziessow D, Scherer H, Wolf KJ (1991) 31P nuclear magnetic resonance spectroscopy, histology and cytokinetics of a xenografted hypopharynx carcinoma following treatment with cisplatin: Comparison in three sublines with increasing resistance. Br J Cancer 64:485-493
66. Castaing M, Brouant P, Loiseau A, Santelli-Rouvier C, Santelli M, Alibert-Franco S, Mahamoud A, Barbe J (2000) Membrane permeation by multidrug-resistance-modulators and non-modulators: Effects of hydrophobicity and electric charge. J Pharm Pharmacol 52:289-296
67. Lo Y-L (2000) Phospholipids as multidrug resistance modulators of the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochem Pharmacol 60:1381-1390
68. Romsicki Y, Sharom FJ (2001) Phospholipid flippase activity of the reconsituted P-glycoprotein multidrug transporter. Biochemistry 40:6937-6947
69. Senchenkov A, Litvak DA, Cabot MC (2001) Targeting ceramide metabolism - a strategy for overcoming drug resistance. J Natl Cancer Inst 93:347-357
70. Zhou Y, Gottesman M, Pastan I (1999) Domain exchangeability between the multidrug transporter (MDR1) and phosphatidylcholine flippase (MDR2). Mol Pharmacol 56:997-1004
71. Stein U, Walther W, Shoemaker RH (1996) Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance. Br J Cancer 74:1384-1391
72. Monti F, Lalli E, Bontadini A, Szymczuk S, Pini E, Tononi A, Fattori PP, Facchini A, Ravaioli A (1994) Synergism between gamma interferon and doxorubicin in a human MDR colon adenocarcinoma cell line. J Chemother 6:337-342
73. Basting R, Corvin S, Haendel D, Hinke A, Schmidt D (1999) Adjuvant immunotherapy in renal cell carcinoma - comparison of interferon alpha treatment with an untreated control. Anticancer Res 19:1545-1548
74. Buzogany I, Czvalinga I, Gotz F (1997) Results of ambulatory mono- and combined interferon therapy in advanced kidney tumors. Orv Hetil 138:67-70
75. Jelic S, Babovic N, Stamatovic L, Kreacic M, Matkovic S, Popov I (2001) Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures. Med Oncol 18:189-195
76. Ling V (1997) Multidrug resistance: Molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 40:S3-S8
77. Data Sheet Dilzem, Medsafe, 2002 (www.medsafe.govt.nz/Datasheet-Page.htm)
78. Bennett CL, Vogelzang NJ, Ratain MJ, Reich SD (1986) Hyponatremia and other toxic effects during a phase I trial of recombinant human gamma interferon and vinblastine. Cancer Treat Rep 70:1081-1084
79. Gutterman JU, Fine S, Quesada J, Horning SJ, Levine JF, Alexanian R, Bernhardt L, Kramer M, Spiegel H, Colburn W, Trown P, Merigan T, Dziewanowski Z (1982) Recombinant leukocyte A interferon: Pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med 96:549-556
80. Nanus DM, Pfeffer LM, Bander NH, Bahri S, Albino AP (1990) Antiproliferative and antitumor effects of a-interferon in renal cell carcinomas: Correlation with the expression of a kidney-associated differentiation glycoprotein. Cancer Res 50:4190-4194